-
Mashup Score: 5Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC - 3 month(s) ago
Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 7
Kashul Parikh, MBBS, discusses research efforts dedicated to leveraging antibody-drug conjugates with varying targets in lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Leveraging ADCs in Lung Cancer: Snapshot of Existing Challenges and Opportunities @kaushalpar @MayoCancerCare #lcsm #MedTwitter #oncology https://t.co/TjHBJcTOle
-
-
Mashup Score: 7
Kashul Parikh, MBBS, discusses research efforts dedicated to leveraging antibody-drug conjugates with varying targets in lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Leveraging ADCs in Lung Cancer: Snapshot of Existing Challenges and Opportunities @kaushalpar @MayoCancerCare #lcsm #MedTwitter #oncology https://t.co/TjHBJcTOle
-
-
Mashup Score: 3
Kaushal Parikh, MBBS, discusses treatment advances in early-stage NSCLC including for patients with actionable mutations, and details considerations with adjuvant approaches.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Refining Adjuvant Immunotherapy Use is a Crucial Focus in Early-Stage NSCLC @kaushalpar @MayoCancerCare #lcsm #MedTwitter #oncology https://t.co/wKLU6Emq62
-
-
Mashup Score: 3
Kaushal Parikh, MBBS, discusses treatment advances in early-stage NSCLC including for patients with actionable mutations, and details considerations with adjuvant approaches.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Refining Adjuvant Immunotherapy Use is a Crucial Focus in Early-Stage NSCLC @kaushalpar @MayoCancerCare #lcsm #MedTwitter #oncology https://t.co/wKLU6Emq62
-
-
Mashup Score: 0Atezolizumab Before and After CRT Appears Safe, Effective in Unresectable Stage III NSCLC - 5 month(s) ago
Atezolizumab administered before and following chemoradiation appeared to be safe and efficacious in unresectable stage III non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Atezolizumab Before and After CRT Appears Safe, Effective in Unresectable Stage III NSCLC @JAMAOnc #lcsm #MedTwitter #oncology https://t.co/9dIboSMPIs
-
-
Mashup Score: 2
Kashul Parikh, MBBS, discusses research efforts dedicated to leveraging antibody-drug conjugates with varying targets in lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Leveraging ADCs in Lung Cancer: Snapshot of Existing Challenges and Opportunities @kaushalpar @MayoCancerCare #lcsm #MedTwitter #oncology https://t.co/TjHBJcTOle
-
-
Mashup Score: 3
Kaushal Parikh, MBBS, discusses treatment advances in early-stage NSCLC including for patients with actionable mutations, and details considerations with adjuvant approaches.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Refining Adjuvant Immunotherapy Use is a Crucial Focus in Early-Stage NSCLC @kaushalpar @MayoCancerCare #lcsm #MedTwitter #oncology https://t.co/wKLU6Emq62
-
-
Mashup Score: 0Atezolizumab Before and After CRT Appears Safe, Effective in Unresectable Stage III NSCLC - 5 month(s) ago
Atezolizumab administered before and following chemoradiation appeared to be safe and efficacious in unresectable stage III non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Atezolizumab Before and After CRT Appears Safe, Effective in Unresectable Stage III NSCLC @JAMAOnc #lcsm #MedTwitter #oncology https://t.co/9dIboSMPIs
-
-
Mashup Score: 2FDA Grants Priority Review to Osimertinib for EGFR+ Stage III NSCLC - 7 month(s) ago
The FDA has granted priority review to the supplemental NDA seeking the approval of osimertinib in EGFR-mutated stage III non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
FDA Grants Priority Review to Osimertinib for EGFR+ Stage III NSCLC @US_FDA #lcsm #MedTwitter #oncology https://t.co/lQ4huQC6BE
-
Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC @ipreeshagul @MSKCancercenter #lcsm #MedTwitter #oncology https://t.co/lT9a0ccmlR